Quotient says screening of prototype formulations is crucial to drug delivery

By Natalie Morrison

- Last updated on GMT

Related tags: Drug delivery, Pharmacology

Quotient has stressed the importance of screening prototype formulations early in the development process to ensure efficient drug delivery in later phases.

Speaking to Outsourcing-Pharma at this year’s AAPS conference in Washington, the firm’s VP, pharmaceutical sciences Peter Scholes explained the Rapid Fact program – a service Quotient offers to meet drug delivery challenges.

He told us that the main issues clients present are with soluability and half-life of the drug.

“The key challenge is a lack of in vivo,in vitro​ correlation,” said Scholes.

“It’s easy to develop the tablet in the lab to release over six or 12 hours, but the predictability of that in man is very difficult to asses.

“Quotient allow real-time flexibility because of our ability to make and dose on site.”

Related news

Show more

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

Flexible Filling Solution for CMOs

Flexible Filling Solution for CMOs

Single Use Support GmBH | 18-May-2022 | Insight Guide

Achieving flexibility requires modularity of technologies.

CMOs and CDMOs aspire to be flexible for multiple applications. Efficient automated...

Related suppliers

Follow us


View more